Fenofibric acid

製品コードS4527 バッチS452702

印刷

化学情報

Synonyms

NSC 281318, Trilipix, FNF acid

Storage
(From the date of receipt)

3 years -20°C powder
1 years -80°C in solvent

化学式

C₁₇H₁₅ClO₄

分子量

318.75

CAS No.

42017-89-0

Solubility (25°C)*

体外

DMSO

64 mg/mL (200.78 mM)

Water

Insoluble

Ethanol

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Fenofibric acid（NSC 281318、Trilipix、FNF acid）は、低密度リポタンパク質コレステロールとトリグリセリドを減少させる脂質低下剤として作用するフィブラートです。
in vitro	Fibric acids, active forms of fibrate drugs and activators of peroxisome proliferator-activated receptor-alpha (PPARα), are also known for an HDL-raising effect. Fibric acids enhance fatty acid catabolism and accordingly reduce plasma lipid level, predominantly triglyceride (TG). Fenofibric acid increases the expression of ABCA1 and apoA-I–mediated HDL production. The effect on ABCA1 expression was through the enhancement of the transcription of the ABCA1 gene being dependent on LXR.
in vivo	Fenofibric acid attenuates aberrant increases of circulating EPC(Endothelial Progenitor Cells) in OIR mice. Inhibitory effect of this compound on EPC mobilization in the OIR model is PPARα-dependent. It inhibits hypoxia-induced retinal EPC increase in a PPARα-dependent manner. This chemical decreases CXCR4-positive EPC in the circulation, downregulates the serum SDF-1 level and suppresses HIF-1a and SDF-1 overexpression in the retina.

プロトコル(参考用のみ)

細胞アッセイ	細胞株	RAW264 cells; THP-1 cells
	濃度	0-200 μmol/L
	反応時間	48 h
	実験の流れ	PPAR activators fenofibric acid is dissolved in DMSO and added to the culture medium containing 0.2% BSA. RAW264 cells are washed with PBS and cultured an additional 48 hours in the presence of this compound in DMEM/F-12(1:1) medium containing 2% TCM and 0.2% BSA. During the last 24 hours of the drug treatment, 300 mol/L of dibutyryl cAMP and apoA-I (10 μg/mL) are added to the medium. THP-1 cells are also treated with this compound and apoA-I in 0.2% BSA-RPMI 1640 medium and 0.1% BSA-MEM. Cholesterol and choline-phospholipid released into the medium by apoA-I are determined enzymatically. Adherent cells are dissolved in 0.1 N NaOH for protein determination by bicinchoninic acid protein assay system.
動物実験	動物モデル	C57BL/6J; PPARa-/- mice
	投薬量	10 mg/kg
	投与方法	i.p.

参考

https://pubmed.ncbi.nlm.nih.gov/15790930/
https://pubmed.ncbi.nlm.nih.gov/24845641/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Mechanisms for fibrate lipid-lowering drugs in enhancing bladder cancer immunotherapy by inhibiting CD276 expression [ BMC Cancer, 2025, 25(1):1404]	PubMed: 40887616
Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma [ J Immunother Cancer, 2024, 12(11)e009805]	PubMed: 39581704
Peroxisome Proliferator-Activated Receptor α Activation Protects Retinal Ganglion Cells in Ischemia-Reperfusion Retinas [ Front Med (Lausanne), 2021, 8:788663]	PubMed: 35004756
Immediate-released pelletized solid dispersion containing fenofibrate: Formulation, in vitro characterization, and bioequivalence studies in experimental beagle dogs. [ Int J Pharm, 2019, 570:118661]	PubMed: 31491482

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。